Industry news that matters to you.  Learn more

Archives for April 2012

Frost & Sullivan Honours PathXL with Enabling Technology Award

Based on its recent analysis of web-based software platforms for tissue analysis and quantification, Frost & Sullivan recognise PathXL (Northern Ireland) with the 2012 European Web-based Software Platforms Enabling Technology Award.

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer

Abbott announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.

Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers

Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology announces that Metabolon and Takeda Pharmaceutical Company Limited (TSE: 4502), a global pharmaceutical company, have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.

Time to Breathe a Sigh of Relief

British Columbia is facing a healthcare funding challenge and two of the major drivers contributing to it are emphysema and bronchitis, known together as Chronic Obstructive Pulmonary Disease (COPD). Exacerbations of COPD, or ‘lung attacks’, are currently the leading cause of emergency room visits and hospitalizations among chronic disease sufferers in BC, and across the country. Such lung attacks are also costly to the healthcare system, accounting for over $5.7 billion in direct, and $6.7 billion for indirect, healthcare costs every year in Canada.

PROOF Centre and Adiga Life Sciences Launch Biomarker Discovery Collaboration

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) is working with Adiga Life Sciences to develop better ways of monitoring the effectiveness of novel allergy vaccines through a discovery project aimed at identifying blood-based proteomic and genomic biomarkers. These biomarkers will enhance current understanding of how allergy vaccines work, and will guide the development of molecular tests for the diagnosis and management of allergic rhinitis.